Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: GlobeNewswire
- Firdapse 2019 Net Product Revenues Expected to be Approximately $102 Million - Anticipates Full Year 2020 Firdapse Net Product Revenues to be in the Range of $135 million to $155 million - MuSK-MG Clinical Trial Has Met Enrollment Goals and is on Schedule to Report Top-Line Results in First Half of 2020 - Company is Accelerating Business Development Activities CORAL GABLES, Fla., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today provided a corporate update including preliminary net revenue for 2019, the status of Catalyst’s clinical development programs and other corporate matters. “Catalyst has completed its first year as a commercial-stage company following the successful U.S. launch of Firdapse® (amifampridine) for the treatment of adult
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock [Yahoo! Finance]Yahoo! Finance
- Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to WorkGlobeNewswire
- Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at Truist Financial Co. from $30.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
CPRX
Earnings
- 11/6/24 - Beat
CPRX
Sec Filings
- 11/15/24 - Form 4
- 11/14/24 - Form 144
- 11/14/24 - Form SC
- CPRX's page on the SEC website